Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curtis Triplitt

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Diabetes Care|July 23, 2020
Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus SaxagliptinYuejuan Qin, John Adams, Carolina Solis-Herrera, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 9, 2002
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitusYoshinori Miyazaki, Leonard Glass, Curtis Triplitt, et al.
Diabetes, Obesity & Metabolism|April 14, 2021
Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT studySiham Abdelgani, Curtiss Puckett, John Adams, et al.
Journal of the American College of Cardiology|April 23, 2021
Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art ReviewHenri Honka, Carolina Solis-Herrera, Curtis Triplitt, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetesMariam Alatrach, Christina Agyin, John Adams, et al.
Diabetes Care|January 29, 2010
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metforminRalph A DeFronzo, Curtis Triplitt, Yongming Qu, et al.
Diabetes, Obesity & Metabolism|December 22, 2023
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individualsSiham Abdelgani, Ahmed Khattab, John Adams, et al.
Diabetes Care|April 13, 2013
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer studyCarolina Solis-Herrera, Curtis Triplitt, Jose de Jesús Garduno-Garcia, et al.
Diabetes, Obesity & Metabolism|January 28, 2017
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patientsHussein Al Jobori, Giuseppe Daniele, John Adams, et al.
Diabetes|June 15, 2017
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting GlucoseMuhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Diabetes Care|July 23, 2020
Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus SaxagliptinYuejuan Qin, John Adams, Carolina Solis-Herrera, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 9, 2002
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitusYoshinori Miyazaki, Leonard Glass, Curtis Triplitt, et al.
Diabetes, Obesity & Metabolism|April 14, 2021
Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT studySiham Abdelgani, Curtiss Puckett, John Adams, et al.
Journal of the American College of Cardiology|April 23, 2021
Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art ReviewHenri Honka, Carolina Solis-Herrera, Curtis Triplitt, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetesMariam Alatrach, Christina Agyin, John Adams, et al.
Diabetes Care|January 29, 2010
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metforminRalph A DeFronzo, Curtis Triplitt, Yongming Qu, et al.
Diabetes, Obesity & Metabolism|December 22, 2023
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individualsSiham Abdelgani, Ahmed Khattab, John Adams, et al.
Diabetes Care|April 13, 2013
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer studyCarolina Solis-Herrera, Curtis Triplitt, Jose de Jesús Garduno-Garcia, et al.
Diabetes, Obesity & Metabolism|January 28, 2017
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patientsHussein Al Jobori, Giuseppe Daniele, John Adams, et al.
Diabetes|June 15, 2017
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting GlucoseMuhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, et al.
Pageof 6